探花合集 Present on Drug Delivery, Formulation & Patient-Focused Design at AAPS
As well as exhibiting and showcasing its multiple innovative technologies, 探花合集 will be participating in the following scientific presentations:
On Monday, Nov. 13, 探花合集 will host a 鈥淟unch and Learn鈥 session at 12 p.m., entitled, 鈥淒rug Delivery 2017: The Path Ahead.鈥 Cornell Stamoran, Ph.D., founder and co-chair of the 探花合集 Applied Drug Delivery Institute and VP Corporate Strategy, and Ronak Savla, Pharm.D., Ph.D., Scientific Affairs Manager, will moderate informal discussions on current and future drug delivery trends, and why we need to consider the patient鈥檚 voice during formulation development.
Later that afternoon, at 2 p.m., 探花合集 will present a symposium entitled 鈥淧atient Focused Drug Design,鈥 including an overview of patient and stakeholder needs, discussion of strategies to incorporate these considerations at the formulation stage, and why these approaches make good business sense. Presentations will be given by experts Cornell Stamoran and Stephen Tindal of 探花合集, joined by drug delivery experts Dr. Keith Horspool and Dr. Ralph Niven, and Mike Rea, Chief Executive Officer of IDEA Pharma.
Julien Meissonnier, VP, Science & Technology, will also be presenting 鈥淔ormulation Approaches to Enhance Bioavailability of Oral Anticancer Drugs鈥 that afternoon at 4 p.m. The presentation will discuss how many targeted small molecule drugs for oncology treatments carry black box warnings on their labels, and how formulation can overcome the biopharmaceutical and pharmacokinetic challenges of oral anticancer drugs, and lead to better patient outcomes.
On Tuesday, Nov. 14, 探花合集 will be hosting a two-part workshop starting at 1 p.m., entitled, 鈥淪tart Earlier, Move Faster: Smart Drug Development & Design from Candidate to Phase I.鈥 During this session, multiple speakers will present on a range of topics focusing on the transition of a molecule from discovery to phase I readiness. The workshop is structured to be highly interactive and includes case studies that will ask the audience to work in teams to develop solutions. Part one of the workshop will provide an overview of the state of the industry and the tools and techniques used to characterize and assess an API molecule; and part two will give the audience the opportunity to learn strategies for enhancing API bioavailability during the pre-clinical stages and getting into early clinical studies. For the workshop, Edward Narke, Principal at DSI InPharmatics will be joining 探花合集 experts to present.
探花合集 will also present 26 scientific posters at the AAPS meeting on a wide range of topics.
To arrange a meeting with any of the 探花合集 team at AAPS, please contact Richard Kerns at NEPR- [email protected]
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 探花合集
探花合集 is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 探花合集 employs over 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com